Guided Therapeutics, Inc.
GTHP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -92.9% | 653.8% | -84% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 28.6% | 36.7% | -523.1% | 24.7% |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $1 | $3 | $3 | $2 |
| SG&A Expenses | $2 | $3 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $2 |
| Operating Income | -$2 | -$3 | -$3 | -$2 |
| % Margin | -30,114.3% | -3,527.6% | -25,638.5% | -2,916% |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | $0 |
| Pre-Tax Income | -$2 | -$3 | -$4 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | -$4 | -$2 |
| % Margin | -34,528.6% | -3,560.2% | -33,392.3% | -2,555.6% |
| EPS | -0.045 | -0.074 | -0.15 | -0.18 |
| % Growth | 38.5% | 51% | 16.7% | – |
| EPS Diluted | -0.045 | -0.074 | -0.15 | -0.18 |
| Weighted Avg Shares Out | 57 | 51 | 33 | 13 |
| Weighted Avg Shares Out Dil | 57 | 51 | 33 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$3 | -$4 | -$1 |
| % Margin | -27,728.6% | -3,189.8% | -28,361.5% | -1,134.6% |